This study analyzes 20 years of data from the Food and Drug Administration’s Adverse Event Reporting System (FAERS) to reveal ...

No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.

Review of recent advances in biomimetic drug delivery for rheumatoid arthritis, highlighting targeted nanomedicine strategies ...

A six-year cohort study shows low muscle strength, not sarcopenia, is linked to increased falls risk in patients with ...

Paternal exposure to methotrexate before conception is not linked to increased risks for adverse birth outcomes, but exposures to some other immunosuppressants and biologics do carry risks.

Use of disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis ...

Concomitant IBD reduces disease control and treatment response among patients with PsA receiving biologic therapy.

Compared with cDMARDs, bDMARDs are associated with lower risks for cardiovascular events and all-cause mortality in psoriatic arthritis.

Researchers identified risks and contributing factors for preterm birth among pregnant women with psoriatic arthritis.

Patients with SARDs face an increased risk for hospitalization during RSV infection, with greater risk linked to frailty, concurrent infection, and higher comorbidity burden.

Rheumatoid arthritis (RA) may cause hair loss due to medications, other autoimmune diseases, or stress. Learn about the causes and remedies to manage hair thinning linked to RA.